An analysis of these biomarkers found increased levels of CSF tau among patients suffering from acute ischemic events detected by combined clinical and MRI assessments.9 CSF p-tau levels were similar between individuals with MCI and those with stroke, suggesting some neurodegeneration within both groups, although this biomarker was more altered in AD. The gene discussed is MAPT; the disease is stroke disorder.